We are pleased to announce our partnership with Noble Capital Markets Inc., a U.S. investment bank with extensive expertise in biotech financing. This collaboration aligns with PolTREG’s strategic plans for growth in the United States.
“PolTREG is financially stable, with secured funding for our priority projects in the coming quarters. Over the years, we have developed a robust platform for multiple cell therapies, including polyclonal TREGs, CAR-TREGs, allogeneic TREGs, antigen-specific TREGs, and TCR TREGs. To fully unlock our potential, we are focusing on the U.S. market, which offers tremendous opportunities for capital access and collaborations with global pharmaceutical leaders. After numerous discussions with investment banks and financial advisors, we chose Noble Capital Markets for their deep knowledge and experience in the biotech sector.” – Prof. Piotr Trzonkowski, CEO & Co-founder of PolTREG S.A.
Our plans for growth in the U.S. also include recently signed agreements: ✅ In March, PolTREG established a strategic collaboration with Antion Biosciences (Switzerland) to develop the next generation of allogeneic TREG therapies ✅ In February, we began cooperation with Kinexum Services LLC (U.S.) for strategic regulatory advisory regarding TREG therapy registration in the United States.
We are also engaged in discussions with leading U.S. clinical centers to explore potential collaborations.